Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis
Severe acute respiratory syndrome coronavirus 2 has spread rapidly around the globe. However, despite its high pathogenicity and transmissibility, the severity of the associated disease, COVID-19, varies widely. While the prognosis is favorable in most patients, critical illness, manifested by respiratory distress, thromboembolism, shock, and multi-organ failure, has been reported in about 5% of cases. Several studies have associated poor COVID-19 outcomes with the exhaustion of natural killer cells and cytotoxic T cells, lymphopenia, and elevated serum levels of D-dimer. In this article, we propose a common pathophysiological denominator for these negative prognostic markers, endogenous, angiotensin II toxicity. We hypothesize that, like in avian influenza, the outlook of COVID-19 is negatively correlated with the intracellular accumulation of angiotensin II promoted by the viral blockade of its degrading enzyme receptors. In this model, upregulated angiotensin II causes premature vascular senescence, leading to dysfunctional coagulation, and immunity. We further hypothesize that angiotensin II blockers and immune checkpoint inhibitors may be salutary for COVID-19 patients with critical illness by reversing both the clotting and immune defects (Graphical Abstract)..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Frontiers in Immunology - 11(2020) |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Adonis Sfera [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Angiotensin II |
---|
doi: |
10.3389/fimmu.2020.01472 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ006225683 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ006225683 | ||
003 | DE-627 | ||
005 | 20230309200525.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fimmu.2020.01472 |2 doi | |
035 | |a (DE-627)DOAJ006225683 | ||
035 | |a (DE-599)DOAJ5b5db231bff34309b2d3f01d7ab1c7fc | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC581-607 | |
100 | 0 | |a Adonis Sfera |e verfasserin |4 aut | |
245 | 1 | 0 | |a Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Severe acute respiratory syndrome coronavirus 2 has spread rapidly around the globe. However, despite its high pathogenicity and transmissibility, the severity of the associated disease, COVID-19, varies widely. While the prognosis is favorable in most patients, critical illness, manifested by respiratory distress, thromboembolism, shock, and multi-organ failure, has been reported in about 5% of cases. Several studies have associated poor COVID-19 outcomes with the exhaustion of natural killer cells and cytotoxic T cells, lymphopenia, and elevated serum levels of D-dimer. In this article, we propose a common pathophysiological denominator for these negative prognostic markers, endogenous, angiotensin II toxicity. We hypothesize that, like in avian influenza, the outlook of COVID-19 is negatively correlated with the intracellular accumulation of angiotensin II promoted by the viral blockade of its degrading enzyme receptors. In this model, upregulated angiotensin II causes premature vascular senescence, leading to dysfunctional coagulation, and immunity. We further hypothesize that angiotensin II blockers and immune checkpoint inhibitors may be salutary for COVID-19 patients with critical illness by reversing both the clotting and immune defects (Graphical Abstract). | ||
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a cellular senescence | |
650 | 4 | |a angiotensin II | |
650 | 4 | |a prognosis | |
650 | 4 | |a critical illness | |
650 | 4 | |a immune checkpoint inhibitors | |
653 | 0 | |a Immunologic diseases. Allergy | |
700 | 0 | |a Carolina Osorio |e verfasserin |4 aut | |
700 | 0 | |a Nyla Jafri |e verfasserin |4 aut | |
700 | 0 | |a Eddie Lee Diaz |e verfasserin |4 aut | |
700 | 0 | |a Jose E. Campo Maldonado |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Frontiers in Immunology |d Frontiers Media S.A., 2011 |g 11(2020) |w (DE-627)DOAJ000031690 |x 16643224 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2020 |
856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2020.01472 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/5b5db231bff34309b2d3f01d7ab1c7fc |z kostenfrei |
856 | 4 | 0 | |u https://www.frontiersin.org/article/10.3389/fimmu.2020.01472/full |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1664-3224 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 11 |j 2020 |